ACHILLES THERAPEUTICS PL-ADR (ACHL) Stock Price & Overview
NASDAQ:ACHL • US00449L1026
Current stock price
The current stock price of ACHL is 1.48 USD. Today ACHL is up by 0.68%. In the past month the price increased by 6.47%. In the past year, price increased by 15.63%.
ACHL Key Statistics
- Market Cap
- 63.202M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -1.65
- Dividend Yield
- N/A
ACHL Stock Performance
ACHL Stock Chart
ACHL Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to ACHL. When comparing the yearly performance of all stocks, ACHL is one of the better performing stocks in the market, outperforming 94.71% of all stocks.
ACHL Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to ACHL. ACHL has a great financial health rating, but its profitability evaluates not so good.
ACHL Earnings
ACHL Forecast & Estimates
6 analysts have analysed ACHL and the average price target is 6.12 USD. This implies a price increase of 313.51% is expected in the next year compared to the current price of 1.48.
ACHL Groups
Sector & Classification
ACHL Financial Highlights
Over the last trailing twelve months ACHL reported a non-GAAP Earnings per Share(EPS) of -1.65. The EPS increased by 12.7% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -54.52% | ||
| ROE | -64.84% | ||
| Debt/Equity | 0 |
ACHL Ownership
ACHL Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.26 | 364.897B | ||
| AMGN | AMGEN INC | 15.33 | 183.284B | ||
| GILD | GILEAD SCIENCES INC | 16.01 | 172.309B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.9 | 109.705B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.59 | 80.376B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 43.86 | 42.375B | ||
| INSM | INSMED INC | N/A | 35.141B | ||
| NTRA | NATERA INC | N/A | 29.66B | ||
| BIIB | BIOGEN INC | 11.19 | 25.773B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.48 | 24.795B | ||
| MRNA | MODERNA INC | N/A | 19.79B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.082B | ||
| INCY | INCYTE CORP | 12.52 | 18.645B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About ACHL
Company Profile
Achilles Therapeutics Plc is a biopharmaceutical company engaged in developing transformative precision T-cell therapies to treat multiple types of solid tumors. The firm has been developing artificial intelligence (AI)-powered precision T cell therapies targeting clonal neoantigens: protein markers unique to the individual that are expressed on the surface of every cancer cell. The firm has used DNA sequencing data from each patient, together with its proprietary PELEUS bioinformatics platform, to identify clonal neoantigens specific to that patient, to enable and support development of product candidates specifically targeting those clonal neoantigens.
Company Info
IPO: 2021-03-31
ACHILLES THERAPEUTICS PL-ADR
245 Hammersmith Road, Gunnels Wood Road
London W6 8PW GB
CEO: Iraj Ali
Employees: 210
Phone: 442081544600
ACHILLES THERAPEUTICS PL-ADR / ACHL FAQ
What does ACHL do?
Achilles Therapeutics Plc is a biopharmaceutical company engaged in developing transformative precision T-cell therapies to treat multiple types of solid tumors. The firm has been developing artificial intelligence (AI)-powered precision T cell therapies targeting clonal neoantigens: protein markers unique to the individual that are expressed on the surface of every cancer cell. The firm has used DNA sequencing data from each patient, together with its proprietary PELEUS bioinformatics platform, to identify clonal neoantigens specific to that patient, to enable and support development of product candidates specifically targeting those clonal neoantigens.
What is the stock price of ACHILLES THERAPEUTICS PL-ADR today?
The current stock price of ACHL is 1.48 USD. The price increased by 0.68% in the last trading session.
Does ACHILLES THERAPEUTICS PL-ADR pay dividends?
ACHL does not pay a dividend.
What is the ChartMill technical and fundamental rating of ACHL stock?
ACHL has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Is ACHILLES THERAPEUTICS PL-ADR (ACHL) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on ACHL.
Can you provide the ownership details for ACHL stock?
You can find the ownership structure of ACHILLES THERAPEUTICS PL-ADR (ACHL) on the Ownership tab.